Trial · NCT05437510
Trial comparisons11
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
1 to 11 of 11
Download this page as JSON| Comparison | Source |
|---|---|
| Nirsevimab vs No Intervention: Number of Participants With Very Severe Respiratory Syncytial Virus Lower Respiratory Tract Infection Through the Respiratory Syncytial Virus Season | Trial comparisons |
| Nirsevimab vs No Intervention: Number of Participants With Immediate Treatment-Emergent Adverse Events (TEAEs) | Trial comparisons |
| Nirsevimab vs No Intervention: Number of Participants With Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) Hospitalization Through the Respiratory Syncytial Virus Season | Trial comparisons |
Nirsevimab vs No Intervention: Number of Participants With Respiratory Syncytial Virus Lower Respiratory Tract Infection Hospitalization From Days 366 to 731 Post-dosing/Randomization (for United Kingdom Reconsented Participants) | Trial comparisons |
Nirsevimab vs No Intervention: Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection From Days 366 to 731 Post-dosing/Randomization (for United Kingdom Reconsented Participants) | Trial comparisons |
| Nirsevimab vs No Intervention: Number of Participants With Recurrent Wheeze (for United Kingdom Reconsented Participants) | Trial comparisons |
| Nirsevimab vs No Intervention: Number of Participants With Non-Serious Treatment-Emergent Adverse Events | Trial comparisons |
| Nirsevimab vs No Intervention: Number of Participants With Hospitalization for All-Cause Lower Respiratory Tract Infection From Days 181 to 366 Post-dosing/Randomization | Trial comparisons |
| Nirsevimab vs No Intervention: deaths from any cause | Trial comparisons |
| Nirsevimab vs No Intervention: Number of Participants With Treatment-Related Serious Adverse Event (for United Kingdom Reconsented Participants) | Trial comparisons |
| Nirsevimab vs No Intervention: serious adverse events | Trial comparisons |
trials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05437510/comparisons